Merck and Eisai's experimental combination treatment helped extend the time certain patients with advanced kidney cell cancer ...

Merck on Tuesday said a Phase 3 study evaluating the dual oral regimen of Welireg plus Lenvima met one of its primary endpoints of progression-free survival for the treatment of patients with advanced ...

Merck and Eisai's experimental combination treatment helped extend the time certain patients with advanced kidney cell cancer ...

Xencor's clear cell renal cell carcinoma treatment demonstrated evidence of anti-tumor activity in a phase 1 trial.

Sweis, MD, and participants discussed their impressions of combination trials in non–clear cell renal cell carcinoma. Non-clear cell renal cell carcinoma (nccRCC) is a less common disease state than ...

Investing.com -- Xencor Inc (NASDAQ:XNCR) stock rose 4.9% after the clinical-stage biopharmaceutical company reported encouraging initial results from its Phase 1 trial of XmAb819 in patients with ...

January 27, 2012 — The US Food and Drug Administration (FDA) has approved axitinib (Inlyta, Pfizer) for the treatment of advanced renal cell carcinoma (RCC) that has progressed after first-line ...

The US Food and Drug Administration (FDA) has approved lenvatinib (Lenvima, Eisai), in combination with everolimus, for the treatment of patients with advanced renal cell carcinoma who were previously ...

Xencor, Inc. recently presented initial results from its Phase 1 dose-escalation study of XmAb819, an ENPP3 x CD3 bispecific antibody, in patients with advanced clear cell renal cell carcinoma at the ...

Novel approaches in molecular imaging and targeted therapeutics are transforming the management of renal cell carcinoma (RCC) and urothelial carcinoma (UC). This review focuses on three key areas of ...

Impact of Funding Source on Long-Term Outcomes in Prostate Cancer: Analysis of a Large Public Database From Sao Paulo, Brazil A retrospective study was conducted involving 689 patients with mRCC ...